ELK1 (Ab-389) Antibody

What is ELK1 and why is it significant in cellular signaling pathways?

ELK1 functions as a critical member of the Ets family of transcription factors and belongs to the ternary complex factor (TCF) subfamily. The significance of ELK1 stems from its role in forming a ternary complex by binding to the serum response factor (SRF) and the serum response element (SRE) in the promoter region of the c-fos proto-oncogene. This interaction makes ELK1 a nuclear target for the ras-raf-MAPK signaling cascade, positioning it as a crucial mediator of cellular responses to extracellular stimuli. The protein is predominantly expressed in lung and testis tissues, although its signaling functions extend to multiple cell types . ELK1's biological importance is further underscored by the existence of alternatively spliced transcript variants that encode the same protein, suggesting evolutionary conservation of its function .

What are the key applications for ELK1 (Ab-389) Antibody in research?

ELK1 (Ab-389) Antibody serves multiple experimental applications across various molecular and cellular techniques:

The antibody demonstrates reactivity across human, mouse, and rat samples, making it suitable for comparative studies across these species . For phospho-specific variants targeting Ser389, the antibody enables investigation of post-translational modifications crucial for ELK1 function in signaling pathways .

What are the optimal storage and handling conditions for ELK1 (Ab-389) Antibody?

Proper storage and handling of ELK1 (Ab-389) Antibody are essential to maintain its activity and specificity:

• Short-term storage (up to 6 months): Store at 4°C in the supplied buffer containing phosphate-buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide, and 50% glycerol

• Long-term storage: Store at -20°C in aliquots to minimize freeze-thaw cycles

• Thawing procedure: Allow antibody to thaw completely at room temperature before use

• Working concentration: The antibody is typically supplied at 1.0mg/mL and should be diluted appropriately for specific applications

• Stability concerns: Repeated freeze-thaw cycles should be strictly avoided as they can lead to protein denaturation and loss of antibody activity

When preparing working dilutions, always use fresh, sterile buffers and maintain aseptic conditions to prevent microbial contamination.

How do phospho-specific ELK1 antibodies differ from total ELK1 antibodies in experimental applications?

The distinction between phospho-specific and total ELK1 antibodies is crucial for experimental design:

Phospho-specific ELK1 antibodies (e.g., phospho-Ser389):

• Recognize ELK1 only when phosphorylated at specific residues (e.g., Ser389)

• Are generated using synthetic phosphopeptides corresponding to regions surrounding the phosphorylation site

• Undergo affinity purification via sequential chromatography on phospho- and non-phospho-peptide affinity columns to ensure specificity

• Are ideal for studying activation states of ELK1 in response to stimuli

• Provide temporal information about signaling events

Total ELK1 antibodies:

• Recognize ELK1 regardless of phosphorylation status

• Are typically generated against larger protein fragments or domains

• Can be used as controls to determine total protein expression levels

• Allow normalization of phospho-specific signals in quantitative analyses

What controls should be included when using ELK1 (Ab-389) Antibody in experimental procedures?

Rigorous experimental design requires appropriate controls when using ELK1 (Ab-389) Antibody:

Positive controls:

• Lysates from cell lines known to express ELK1 (lung or testis-derived cell lines)

• Recombinant ELK1 protein (for standard curves in quantitative applications)

• Mitogen-stimulated cells that induce ELK1 phosphorylation

Negative controls:

• Isotype control antibodies (rabbit IgG at equivalent concentration)

• Lysates from cell lines with ELK1 knockdown

• Blocking peptide competition assays to confirm specificity

Phosphorylation-specific controls:

• Samples treated with lambda phosphatase to remove phosphorylation

• Comparison of stimulated versus non-stimulated cells

• Cells treated with MAPK inhibitors to prevent ELK1 phosphorylation

Including these controls helps validate antibody specificity, minimize false positives, and ensure accurate interpretation of experimental results.

How can phospho-specific ELK1 antibodies be effectively used to study MAPK pathway activation dynamics?

Phospho-specific ELK1 antibodies serve as powerful tools for dissecting MAPK pathway activation kinetics:

The ELK1 protein undergoes phosphorylation at multiple sites, with Ser383 and Ser389 being preferentially targeted by MAPK1 (ERK2). This phosphorylation event is a critical readout of active MAPK signaling. A methodological approach to study this pathway involves:

• Time-course experiments: Treat cells with pathway activators (e.g., growth factors, mitogens) and collect samples at intervals ranging from 5 minutes to 24 hours

• Pathway inhibition: Pre-treat cells with specific MAPK pathway inhibitors (U0126, PD98059) to confirm pathway specificity

• Quantitative Western blotting: Use phospho-Ser389 ELK1 antibodies alongside total ELK1 antibodies to calculate phosphorylation/total protein ratios

• Multiplexed analysis: Combine phospho-ELK1 detection with other MAPK pathway components (phospho-ERK, phospho-RSK) to build pathway activation profiles

This approach has revealed that ELK1 phosphorylation on mitogenic stimulation occurs at C-terminal serine and threonine residues, with Ser383 and Ser389 being the preferred sites for MAPK1 . In vitro studies demonstrate that this phosphorylation by MAPK1 potentiates ternary complex formation with serum response factors, SRE and SRF, providing a direct link between MAPK signaling and transcriptional regulation .

What methodological approaches optimize detection of ELK1 phosphorylation at Ser389?

Detecting phosphorylation at Ser389 requires specialized techniques to maximize sensitivity and specificity:

Sample preparation protocol:

• Harvest cells rapidly to preserve phosphorylation states (cold PBS with phosphatase inhibitors)

• Lyse cells in buffer containing phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate)

• Maintain samples at 4°C throughout processing

• Include protease inhibitors to prevent degradation

• Normalize protein concentration precisely before immunoblotting

For immunohistochemistry and immunofluorescence applications:

• Fixation with 4% paraformaldehyde preserves phospho-epitopes better than formalin

• Antigen retrieval using citrate buffer (pH 6.0) enhances detection of phospho-ELK1

• Signal amplification systems (e.g., tyramide) can increase detection sensitivity

• Comparing adjacent serial sections stained with phospho-specific and total ELK1 antibodies

When using phospho-Ser389 antibodies, the synthetic phosphopeptide sequence P-R-Sp-P-A corresponds to residues surrounding the S389 phosphorylation site . This specific sequence recognition provides high specificity when the antibody has been properly purified via sequential chromatography on phospho- and non-phospho-peptide affinity columns .

How can ELK1 (Ab-389) Antibody be utilized to investigate ELK1's role in adipogenesis?

ELK1 plays a crucial role in adipocyte differentiation through the insulin signaling pathway:

Experimental approach for studying ELK1 in adipogenesis:

• Cell model selection: Use 3T3-L1 preadipocytes or embryonic fibroblasts

• Differentiation protocol: Treat cells with adipogenic cocktail (insulin, dexamethasone, IBMX)

• Time-course analysis: Monitor ELK1 phosphorylation status during differentiation phases

• Functional manipulation: Use ELK1 knockdown or overexpression of wild-type vs. S383A/S389A mutant

• Downstream target analysis: Examine effects on adipogenic transcription factors (Krox20, C/EBPβ, PPARγ)

Research has demonstrated that phosphorylation of ELK1 at Ser383 and Ser389 is critical for adipogenesis. The mutation of these two serine residues to alanine significantly inhibits ELK1 activity in reporter assays . More importantly, overexpression of this S383A/S389A mutant in 3T3-L1 cells severely reduces adipocyte differentiation (only 5% differentiation compared to 30% with wild-type ELK1) . This dominant-negative effect confirms the essential role of ELK1 phosphorylation in adipogenesis.

The methodology can be extended to investigate how ELK1 interacts with the Mediator complex subunit MED23, as this interaction is strengthened by ELK1 phosphorylation and is crucial for transducing insulin signaling during adipocyte differentiation .

What technical challenges exist in studying ELK1-MED23 interaction, and how can antibody-based approaches address them?

Investigating the ELK1-MED23 interaction presents several technical challenges that can be addressed with specialized approaches:

Challenges and solutions:

• Weak basal interaction: The interaction between ELK1 and MED23 is typically weak under basal conditions

  • Solution: Stimulate cells with activators of the MAPK pathway to enhance phosphorylation-dependent interaction

• Phosphorylation dependency: The interaction is strengthened by ELK1 phosphorylation

  • Solution: Use GST-ELK1 fusion proteins phosphorylated in vitro by ERK2 for pull-down assays

• Complex formation dynamics: The temporal nature of complex formation is difficult to capture

  • Solution: Employ proximity ligation assays (PLA) with both anti-ELK1 and anti-MED23 antibodies to detect transient interactions in situ

• Co-immunoprecipitation efficiency: Traditional co-IP may not efficiently capture the interaction

  • Solution: Utilize crosslinking approaches prior to immunoprecipitation with ELK1 (Ab-389) Antibody

• Specificity of detection: Ensuring the detected interaction is specific

  • Solution: Compare wild-type ELK1 with the S383A/S389A mutant as a negative control

Research has shown that ERK-phosphorylated GST-ELK1 activation domain binds to immobilized MED23 protein, whereas non-phosphorylated GST-ELK1 does not . In cellular contexts, cotransfection of MYC-ELK1 and FLAG-MED23 expression plasmids results in weak interaction, but this interaction is significantly strengthened when an active MEKK expression plasmid is also cotransfected . These findings demonstrate how phosphorylation status critically regulates protein-protein interactions in signaling complexes.

How can ELK1 phosphorylation status serve as a readout for cellular responses to diverse stimuli?

ELK1 phosphorylation serves as a convergence point for multiple signaling pathways, making it a valuable readout for cellular responses:

Methodological approach:

• Stimulus selection: Test various stimuli including growth factors (EGF, FGF), stress inducers (UV, oxidative stress), and cytokines

• Phospho-specific detection: Use antibodies against different ELK1 phosphorylation sites (Ser383, Ser389)

• Pathway delineation: Combine with inhibitors of specific kinases (MEK, JNK, p38)

• Temporal analysis: Track phosphorylation kinetics to distinguish between transient and sustained responses

• Single-cell analysis: Use phospho-specific immunofluorescence to assess cell-to-cell variation in responses

ELK1 can be phosphorylated by multiple kinases, with each kinase targeting specific residues or combinations of residues:

• MAPK1 (ERK2) phosphorylates Ser383 and Ser389

• MAPK8/9 (JNK) phosphorylates Ser383

• CAMK4, MAPK11, MAPK12, and MAPK14 (p38 isoforms) can also phosphorylate and activate ELK1

• Upon bFGF stimulus, PAK1 can phosphorylate ELK1

This pattern of differential phosphorylation provides a "molecular barcode" that can distinguish between different upstream stimuli and pathway activations. For instance, mitogenic stimulation leads to MAPK1-mediated phosphorylation, while stress stimuli might preferentially activate the JNK or p38 pathways . The functional consequence of phosphorylation includes loss of sumoylation and restoration of transcriptional activator activity, making phospho-ELK1 detection a functional readout of transcriptional potentiation .

What are common issues encountered when using ELK1 (Ab-389) Antibody, and how can they be resolved?

Researchers frequently encounter specific challenges when working with ELK1 antibodies:

When working specifically with phospho-Ser389 antibodies, remember that the antibody detects ELK1 only when phosphorylated at Serine 389 . Ensuring proper sample handling to preserve phosphorylation status is therefore critical for successful results.

How can specificity of ELK1 (Ab-389) Antibody be validated in experimental systems?

Validation of antibody specificity is essential for reliable experimental outcomes:

Recommended validation strategy:

• Peptide competition assay: Pre-incubate antibody with immunizing phosphopeptide (sequence: P-R-Sp-P-A) to block specific binding sites

• Phosphatase treatment: Treat one sample with lambda phosphatase to remove phosphorylation and compare with untreated sample

• Knockdown/knockout controls: Use siRNA-mediated knockdown or CRISPR/Cas9 knockout of ELK1 to confirm specificity

• Stimulus-response validation: Compare unstimulated cells with those treated with known MAPK pathway activators

• Cross-species validation: Test antibody reactivity across human, mouse, and rat samples to confirm conservation of epitope recognition

For phospho-specific antibodies, additional validation steps include comparing wild-type ELK1 with phospho-deficient mutants (S383A/S389A) after stimulation . The phospho-specific antibody should detect only the wild-type protein after pathway activation but not the mutant protein, confirming both the specificity of the antibody and the importance of these phosphorylation sites for ELK1 function.

What emerging applications of ELK1 (Ab-389) Antibody show promise for advanced research?

Several cutting-edge applications are expanding the utility of ELK1 antibodies in research:

• Single-cell phospho-proteomics: Combining phospho-specific ELK1 antibodies with mass cytometry (CyTOF) allows simultaneous detection of multiple phosphorylation events at single-cell resolution

• Live-cell imaging: Development of cell-permeable ELK1 nanobodies conjugated to fluorescent reporters could enable real-time monitoring of ELK1 phosphorylation dynamics

• Proximity-based protein interaction mapping: Using ELK1 antibodies in BioID or APEX2 proximity labeling approaches to identify novel interaction partners in different cellular contexts

• Chromatin immunoprecipitation sequencing (ChIP-seq): Employing ELK1 (Ab-389) Antibody to map genome-wide binding sites of ELK1 in different phosphorylation states

• Therapeutic target validation: Using phospho-specific antibodies to monitor ELK1 activation in disease models and after drug treatment

These approaches will help address unresolved questions about ELK1 function beyond its established roles in the MAPK pathway and adipogenesis . The protein's involvement in other cellular processes and its potential as a biomarker for pathway activation in disease states represent exciting areas for future investigation.

How might ELK1 phosphorylation status inform our understanding of disease mechanisms?

ELK1 phosphorylation dynamics may provide insights into various disease mechanisms:

• Cancer biology: Aberrant MAPK pathway activation is a hallmark of many cancers, and ELK1 phosphorylation status could serve as a downstream readout of this activation

• Metabolic disorders: Given ELK1's role in adipogenesis and insulin signaling, its phosphorylation patterns may reflect altered metabolic states in conditions like diabetes or obesity

• Neurodegenerative diseases: As a transcription factor downstream of growth factor signaling, ELK1 activity might be altered in conditions with compromised trophic support

• Inflammatory disorders: The intersection of stress-activated protein kinases with ELK1 phosphorylation suggests potential roles in inflammatory signaling cascades

• Drug resistance mechanisms: Changes in ELK1 phosphorylation could indicate rewiring of signaling networks in therapy-resistant cells

Methodologically, researchers could use phospho-specific ELK1 antibodies in tissue microarrays or patient-derived samples to correlate phosphorylation patterns with disease progression or treatment response. The integration of these findings with other molecular data could yield comprehensive insights into disease mechanisms and identify new therapeutic targets or biomarkers.